F.D.A. Panelists Call for Removal of Warnings on Menopause Treatments

The FDA's panel of experts has called for the removal of warnings on menopausal hormone therapy (MHT) treatments. The panel argued that the risks associated with MHT have been exaggerated, leading many women to avoid these treatments, which can provide significant benefits. Dr. Marty Makary, the FDA commissioner, stated that the agency has been too cautious in its approach to MHT, leading to unnecessary fear among women. The panel reviewed the latest scientific evidence and concluded that the benefits of MHT, such as relieving menopausal symptoms and reducing the risk of osteoporosis, outweigh the potential risks, which are lower than previously thought. The panel's recommendation aims to encourage more women to consider MHT as a viable option for managing menopausal symptoms and improving their overall health. This decision reflects the ongoing effort to ensure that the regulatory approach to MHT is based on the most up-to-date and balanced assessment of the available evidence.